Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Breast 4Other solid neoplasm 2Gastrointestinal 2CNS 2

Conditions

Small Cell Lung Carcinoma 1Oligodendroglioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × etirinotecan pegol × CNS × Clear all
NCT02312622 2023-12-12

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Stanford University

Phase 2 Completed
27 enrolled 19 charts
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Stanford University

Phase 2 Completed
20 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡